search
Back to results

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2)

Primary Purpose

Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV

Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Docetaxel
Ganetespib
Sponsored by
Synta Pharmaceuticals Corp.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-Small-Cell Lung Adenocarcinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)
  • Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1
  • Prior therapy defined as 1 prior systemic therapy for advanced disease
  • Documented disease progression during or following most first line therapy for advanced disease
  • Adequate hematologic, hepatic, renal function

Exclusion Criteria:

  • Epidermal growth factor receptor (EGFR) mutations
  • Anaplastic lymphoma kinase (ALK) translocations
  • Predominantly squamous, adenosquamous or unclear histologic type
  • Active or untreated central nervous system (CNS) metastases
  • Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
  • Serious cardiac illness or medical conditions
  • Pregnant or lactating women
  • Uncontrolled intercurrent illness

Sites / Locations

  • Arizona Oncology Associates PC- NAHOA
  • Arizona Oncology Associates, PC- NAHOA
  • Northern Arizona Hematology & Oncology Associates
  • Arizona Clinical Research Center, Inc.
  • Pacific Cancer Medical Center, Inc
  • Comprehensive Blood & Cancer Center
  • City of Hope Comprehensive Breast Cancer Center
  • UC San Diego Moores Cancer Center
  • Loma Linda University Cancer Center
  • VA Greater Los Angeles Healthcare System
  • Ronald Reagan UCLA Medical Center
  • St. Joseph Hospital, Center for Cancer Prevention and Treatment
  • Cancer Care Associates Medical Group, Inc.
  • UC Davis Medical Center - UC Davis Comprehensive Cancer
  • Santa Barbara Hematology Oncology Medical Group, Inc.
  • City of Hope- South Pasadena
  • Rocky Mountain Cancer Center
  • Eastern Connecticut Hematology Associates
  • Medical Oncology Hematology Consultants, PA
  • Lynn Cancer Institute Center for Hematology Oncology
  • Halifax Health - Medical Center
  • University of Miami Health System Sylvester at Deerfield Beach
  • Memorial Regional Hospital
  • Baptist Health Medical Group Oncology, LLC
  • University of South Florida - H. Lee Moffitt
  • Palm Beach Cancer Institute
  • Emory University - Winship Cancer Institute
  • Northwest Georgia Oncology Centers, PC
  • University Of Chicago Medical Center
  • Cancer Care Specialists of Central Illinois, S.C.
  • Saint Anthony Medical Center
  • Fort Wayne Medical Oncology and Hematology Inc
  • AAMC Oncology and Hematology
  • The Center for Cancer and Blood Disorders (CCBD) - Bethesda
  • The John R Marsh Cancer Center
  • Dana Farber Cancer Institute
  • Dana Farber Cancer Institute
  • Henry Ford Hospital
  • Sparrow Regional Cancer Center
  • St. Luke's Hospital Duluth
  • Frauenshuh Cancer Center
  • St. Louis Cancer Care, LLP - North County
  • Renown Regional Medical Center
  • Hackensack University Medical Center - John Theurer Cancer Center
  • New Mexico Cancer Center
  • North Shore Hematology Oncology Associates
  • Clinical Research Alliance
  • University Of North Carolina At Chapel Hill
  • Novant Health Presbyterian Medical Center
  • New Hanover Regional Medical Center - Zimmer Cancer Center
  • Novant Health Oncology Specialists
  • Tulsa Cancer Institute, PLLC
  • Kaiser Permanente Northwest
  • University of Pittsburgh Medical Center
  • Guthrie Medical Group, PC
  • Rapid City Regional Hospital
  • Prairie Lakes Healthcare System
  • Erlanger Institute for Clinical Research
  • Associates In Oncology and Hematology
  • Thompson Cancer Survival Center
  • Texas Oncology-Arlington North
  • Texas Oncology - Arlington South
  • Texas Oncology, P.A.
  • Texas Oncology, PA
  • Simmons Comprehensive Cancer Center
  • Houston Methodist Hospital Research Institute
  • Millennium Oncology
  • Joe Arrington Cancer Research and Treatment Center
  • Cancer Care Centers Of South Texas
  • Cancer Care Centers Of South Texas
  • Cancer Care Centers of South Texas
  • Texas Oncology - Sherman
  • Providence Regional Medical Center Everett
  • Cancer Care Northwest
  • Northwest Medical Specialties, PLLC
  • Mary Babb Cancer Center
  • Green Bay Oncology, Ltd. - St. Mary's Site
  • Green Bay Oncology
  • Landesklinikum Krems
  • Krankenhaus Der Barmherzigen Schwestern
  • Klinikum Wels-Grieskirchen
  • Bezirkskrankenhaus Kufstein [Onkologie]
  • Allgemeines Krankenhaus Linz
  • Elisabeth Linz Hospital
  • Otto Wagner Spital
  • Sozialmedizinisches Zentrum Baumgartner Höhe
  • AZ Sint-Maarten - Campus Leopoldstraat
  • Clinique Saint-Pierre Ottignies
  • Grand Hôpital de Charleroi - Site Notre-Dame
  • INDC Entité Jolimontoise - Polyclinique de Jolimont
  • CHU Dinant Godinne UCL Namur
  • Algemeen Stedelijk Ziekenhuis - Campus Aalst
  • Cliniques Universitaire Saint-Luc
  • CHR de la Citadelle - Site Citadelle
  • Clinical Centre Banja Luka
  • University Clinical Center Tuzla
  • Clinical Hospital Mostar
  • Clinical Center University of Sarajevo, Clinic of Oncology
  • University Clinical Centre Sarajevo
  • University Clinical Center Tuzla
  • Kantonalna bolnica Zenica
  • Princess Margaret Hospital
  • Mc Gill University-MUHC
  • University Hospital Center Zagreb
  • Opca bolnica Pula
  • Fakultni nemocnice Olomouc
  • Fakultni nemocnice Ostrava
  • Vseobecna fakultni nemocnice v Praze
  • Nemocnice Na Bulovce
  • CHI des Alpes du Sud
  • Centre D'Oncologie Du Pays Basque
  • Centre Hosptalier De Villefranche-Sur-Saone
  • Chi creteil
  • Chu De Grenoble - Hopital Michallon
  • Centre Léon Bérard
  • Groupe Hospitalier Cochin
  • Centre Hospitalier Universitaire de Rennes - Hopital d
  • Hôpital Charles Nicolle
  • CHRU de Strasbourg
  • Universitätsklinikum Freiburg
  • Universiaetsklinikum Ulm
  • Schwarzwald-Baar-Klinikum
  • Asklepios Fachklinik München-Gauting
  • Klinikum Bogenhausen
  • Gesundheitszentrum Wetterau
  • Johann Wolfgang Goethe University Clinic Frankfurt
  • Johann Wolfgang Goethe University Clinic Frankfurt
  • Klinikum Kassel
  • Kliniken der Stadt Köln gGmbH
  • Universitaetsklinikum des Saarlandes
  • Universitätsklinikum Leipzig [Pneumologie]
  • Pneumologisches Forschungsinstitut an der Lungenclinic Gross
  • MVZ Äerzteforum Seestraße
  • Ev. Krankenhaus Bielefeld
  • Klinikum Frankfurt An Der Oder
  • Practice Laack
  • Unikl. Schleswig-Holstein - Lübeck
  • J. Gutenberg Uni.Mainz
  • Medizinische Fakultät Mannheim Uni Heidelberg
  • Gemeinschaftspraxis fuer Haematologie und Onkologie
  • Klinikum Offenbach GmbH
  • Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkó
  • Fejér Megyei Szent György Egyetemi Oktató Kórház
  • Országos Korányi TBC és Pulmonológiai Intézet
  • Semmelweis Egyetem
  • Országos Korányi TBC és Pulmonológiai Intézet
  • Békés Megyei Pándy Kálmán Kórház
  • CRU Hungary Kft.
  • Irccs Irst
  • Presidio Ospedaliero Centrale Belcolle, AUSL Viterbo
  • Azienda Ospedaliera San Gerardo
  • CRO, IRCCS, Istituto Nazionale Tumori
  • Azienda Policlinico Umberto I
  • Policlinico S.Orsola Malpighi, AOU di Bologna
  • AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can
  • Istituto Europeo di Oncologia, Istituto di Ricovero e Cura a
  • Iov-Irccs
  • Ospedale S.Maria della Misericordia, AO di Perugia, Universi
  • Ospedale Guglielmo da Saliceto, AUSL Piacenza
  • Istituti Fisioterapici Ospitalieri Regina Elena
  • Borgo Roma, Policlinico G.Rossi, AOU Integrata Verona
  • Ziekenhuis Assen
  • Ziekenhuis St Jansdal
  • Gelre Ziekenhuis Zutphen
  • academisch ziekenhuis Maastricht
  • Isala Klinieken Zwolle
  • Sint Antoniusziekenhuis, location Utrecht
  • Wojewodzki Szpital Specjalistyczny im. M.Kopernika
  • Medica Pro Familia Sp. z o.o. S.K.A.
  • Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy
  • Centrum Onkologii - Instytut im. Marii Sklodowskiej - Curie
  • Uniwersytecki Szpital Kliniczny w Bialymstoku
  • Szpital Wojewodzki w Lomzy im. Kardynala S. Wyszynskiego
  • Szpital Wojewodzki Zespolony
  • NZOZ Med Polonia
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii
  • Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc
  • Szpital Chorob Pluc im. Sw. Jozefa w Pilchowicach
  • Szpital Specjalistyczny
  • Institutul Oncologic "Prof. Dr. Alex. Trestioreanu"
  • Spitalul Universitar de Urgenta Bucuresti
  • Spitalul Clinic Coltea
  • Institutul Oncologic "Prof.Dr.I.Chiricuta" Cluj Napoca
  • Medisprof
  • Institutul Oncologic "Prof.Dr.I.Chiricuta" Cluj Napoca
  • Centrul de Oncologie Sf. Nectarie
  • Institutul Regional de Oncologie Iasi
  • Oncomed
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Clinical Centre of Serbia
  • Clinical Centre Nis
  • Institute for Oncology and Radiology of Serbia
  • Institute for pulmonary diseases of Vojvodine
  • Clinical Center Kragujevac
  • Univerzitetna klinika za pljucne bolesti in alergijo Golnik
  • Onkoloski institut Ljubljana
  • Xerencia de Xestión Integrada A Coruña Hospital Teresa Herrera
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • H. Son Llàtzer
  • Hospital de Mataró, Consorci Sanitari del Maresme
  • Synta Pharmaceuticals Investigational Site
  • Onkologikoa
  • Hospital Universitari Germans Trias i Pujol
  • H.U. Vall d'Hebrón
  • Synta Pharmaceuticals Investigational Site
  • H.U. Reina Sofía
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Hospital Universitario Ramón y Cajal
  • Synta Pharmaceuticals Investigational Site
  • F. Jiménez Diaz
  • Synta Pharmaceuticals Investigational Site
  • Hospital Madrid Norte Sanchinarro
  • Synta Pharmaceuticals Investigational Site
  • Hospital Universitario Virgen del Rocío
  • Hospital Universitari i Politecnic La Fe
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigative Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site
  • Synta Pharmaceuticals Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Ganetespib and Docetaxel

Docetaxel

Arm Description

Ganetespib (150 mg/m^2) and docetaxel (75 mg/m^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle.

Docetaxel (75 mg/m^2) was administered on Day 1 of a 3-week treatment cycle by 1-hour IV infusion.

Outcomes

Primary Outcome Measures

Overall Survival as of 19 October 2015
Overall survival (OS) was measured from the date of randomization to the date of death from any cause.

Secondary Outcome Measures

Progression-free Survival (PFS) as of 19 October 2015
The progression-free interval is the interval from the date of randomization until tumor progression per modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), clinical progression, or death from any cause in the absence of progressive disease, whichever occurs first. Data represents the investigator's assessment. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Overall Survival (OS) In Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015
OS was measured from the date of randomization to the date of death from any cause. Elevated LDH includes values above the upper limit of normal.
Objective Response Rate (ORR) as of 19 October 2015
Percentage of participants whose best overall response, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was either a complete response (CR) or a partial response (PR). CR was defined as the disappearance (or normalization) of all target lesions. PR was defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.
Disease Control Rate (DCR) as of 19 October 2015
Percentage of participants whose best overall response, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was either a complete response (CR), a partial response (PR), or stable disease (SD). CR was defined as the disappearance (or normalization) of all target lesions. PR was defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of diameters while on study. For participants with a best response of SD, duration of SD must be for at least 6 weeks or 12 weeks.
Kaplan-Meier Estimate of Duration of Response (DOR) as of 19 October 2015
Only participants who achieved a confirmed response (complete response (CR) or partial response (PR)) were included in the DOR analysis. CR was defined as the disappearance (or normalization) of all target lesions. PR was defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.
Progression Free Survival (PFS) in Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015
The progression-free interval is the interval from the date of randomization until tumor progression per modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), clinical progression, or death from any cause in the absence of progressive disease, whichever occurs first. Data represents the investigator's assessment. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Elevated LDH includes values above the upper limit of normal.
Objective Response Rate (ORR) in Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015
Percentage of participants whose best overall response, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was either a complete response (CR) or a partial response (PR). CR was defined as the disappearance (or normalization) of all target lesions. PR was defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Elevated LDH includes values above the upper limit of normal. This study stopped prematurely due to futility and development of this product ceased. The sponsor made a decision at that time to not analyze this outcome. The sponsor no longer has staff or capabilities for further analysis.
Disease Control Rate (DCR) in Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015
Percentage of participants whose best overall response, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was a complete response (CR), a partial response (PR), or stable disease (SD). CR was defined as the disappearance (or normalization) of all target lesions. PR was defined as <=30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of diameters while on study. The duration of SD must be for at least 6 weeks or 12 weeks. Elevated LDH includes values above the upper limit of normal. This study stopped prematurely due to futility and development of this product ceased. The sponsor made a decision at that time to not analyze this outcome. The sponsor no longer has staff or capabilities for further analysis.
Kaplan-Meier Estimate for Time to Emergence of New Metastatic Lesion (TNL) as of 19 October 2015
TNL was defined as time from the randomization date to the first day of radiological progression that included new metastatic lesions. Participants with no new metastatic lesions were censored at the date of the most recent radiological assessment.
Percentage of Participants With Progressive Disease Due to Any New Metastatic Lesion as of 19 October 2015
Progressive disease was due to either new metastatic lesions only or new metastatic lesions and target tumor growth.
Participants With Treatment-Emergent Adverse Events as of 23 December 2015
Treatment-emergent adverse events (AEs) were defined as AEs that occurred from the time of first dose through 30 days after the last dose of study medication. The Investigator graded the severity of AEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) criteria: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death A Serious AE (SAE) is defined as any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or constitutes an important medical event.
Patient-Reported Quality of Life as Measured by the European Quality Of Life - Five Dimensions - Three Levels (EQ-5D-3L) Survey
The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. An overall EQ-5D-3L index was calculated (see EuroQoL website, http://www.euroqol.org/eq-5d-products/eq-5d-3l.html), with an index of 1.0 representing full health and and "0" represents dead, with some health states being worse than dead (<"0"). This study stopped prematurely due to futility and development of this product ceased. The sponsor made a decision at that time to not analyze this outcome. The sponsor no longer has staff or capabilities for further analysis.
Patient-Reported Symptom Improvement as Measured by the Functional Assessment of Cancer Therapy - Lung (FACT-L) Version 4 Test
The FACT-L contains 4 general subscales and a Lung Cancer Subscale (LCS). General subscales include: Physical Well-Being (PWB), Social/ Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). The LCS assesses symptoms commonly reported by lung cancer patients (e.g., shortness of breath, weight loss, and tightness in the chest). The FACT-L total score ranges from 0 to 136, higher scores represent better QOL. Data were not summarized due to the early termination of the study due to futility.

Full Information

First Posted
February 4, 2013
Last Updated
May 26, 2016
Sponsor
Synta Pharmaceuticals Corp.
search

1. Study Identification

Unique Protocol Identification Number
NCT01798485
Brief Title
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Acronym
Galaxy 2
Official Title
A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
May 2016
Overall Recruitment Status
Terminated
Why Stopped
The study was stopped after the first Interim Analysis due to futility.
Study Start Date
April 2013 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Synta Pharmaceuticals Corp.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.
Detailed Description
Preliminary signals of clinical activity of ganetespib as a single agent have been observed in patients with advanced NSCLC. A Phase 2b/3 Study (9090-08) was initiated to evaluate the safety and activity of ganetespib in combination with docetaxel vs. docetaxel alone in NSCLC. Study 9090-08 is ongoing. Results from an interim analysis show that the combination has been well tolerated and an encouraging improvement in efficacy, including overall survival (OS) has been observed. Update: An independent data monitoring committee (DMC) was established to review accumulating unblinded safety data, and efficacy data at two specified Interim Analyses. The DMC monitored the conduct of the trial (including the accrual/retention of patients) and reviewed the risks and benefits. The study was stopped after the first Interim Analysis due to futility. The efficacy portion of this report is based on a 05 October 2015 data cut after the number of protocol-defined death events (336) for the first interim analysis had been achieved. The safety portion is based on the final database locked on 23 December 2015.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
696 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ganetespib and Docetaxel
Arm Type
Experimental
Arm Description
Ganetespib (150 mg/m^2) and docetaxel (75 mg/m^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle.
Arm Title
Docetaxel
Arm Type
Active Comparator
Arm Description
Docetaxel (75 mg/m^2) was administered on Day 1 of a 3-week treatment cycle by 1-hour IV infusion.
Intervention Type
Drug
Intervention Name(s)
Docetaxel
Other Intervention Name(s)
Taxotere, Docecad
Intervention Description
Docetaxel, 75 mg/m^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.
Intervention Type
Drug
Intervention Name(s)
Ganetespib
Other Intervention Name(s)
STA-9090
Intervention Description
Ganetespib, 150 mg/m^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.
Primary Outcome Measure Information:
Title
Overall Survival as of 19 October 2015
Description
Overall survival (OS) was measured from the date of randomization to the date of death from any cause.
Time Frame
up to 36 months
Secondary Outcome Measure Information:
Title
Progression-free Survival (PFS) as of 19 October 2015
Description
The progression-free interval is the interval from the date of randomization until tumor progression per modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), clinical progression, or death from any cause in the absence of progressive disease, whichever occurs first. Data represents the investigator's assessment. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time Frame
up to 36 months
Title
Overall Survival (OS) In Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015
Description
OS was measured from the date of randomization to the date of death from any cause. Elevated LDH includes values above the upper limit of normal.
Time Frame
up to 36 months
Title
Objective Response Rate (ORR) as of 19 October 2015
Description
Percentage of participants whose best overall response, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was either a complete response (CR) or a partial response (PR). CR was defined as the disappearance (or normalization) of all target lesions. PR was defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.
Time Frame
up to 36 months
Title
Disease Control Rate (DCR) as of 19 October 2015
Description
Percentage of participants whose best overall response, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was either a complete response (CR), a partial response (PR), or stable disease (SD). CR was defined as the disappearance (or normalization) of all target lesions. PR was defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of diameters while on study. For participants with a best response of SD, duration of SD must be for at least 6 weeks or 12 weeks.
Time Frame
up to 36 months
Title
Kaplan-Meier Estimate of Duration of Response (DOR) as of 19 October 2015
Description
Only participants who achieved a confirmed response (complete response (CR) or partial response (PR)) were included in the DOR analysis. CR was defined as the disappearance (or normalization) of all target lesions. PR was defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.
Time Frame
up to 36 months
Title
Progression Free Survival (PFS) in Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015
Description
The progression-free interval is the interval from the date of randomization until tumor progression per modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), clinical progression, or death from any cause in the absence of progressive disease, whichever occurs first. Data represents the investigator's assessment. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Elevated LDH includes values above the upper limit of normal.
Time Frame
up to 36 months
Title
Objective Response Rate (ORR) in Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015
Description
Percentage of participants whose best overall response, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was either a complete response (CR) or a partial response (PR). CR was defined as the disappearance (or normalization) of all target lesions. PR was defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Elevated LDH includes values above the upper limit of normal. This study stopped prematurely due to futility and development of this product ceased. The sponsor made a decision at that time to not analyze this outcome. The sponsor no longer has staff or capabilities for further analysis.
Time Frame
up to 36 months
Title
Disease Control Rate (DCR) in Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015
Description
Percentage of participants whose best overall response, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was a complete response (CR), a partial response (PR), or stable disease (SD). CR was defined as the disappearance (or normalization) of all target lesions. PR was defined as <=30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of diameters while on study. The duration of SD must be for at least 6 weeks or 12 weeks. Elevated LDH includes values above the upper limit of normal. This study stopped prematurely due to futility and development of this product ceased. The sponsor made a decision at that time to not analyze this outcome. The sponsor no longer has staff or capabilities for further analysis.
Time Frame
up to 36 months
Title
Kaplan-Meier Estimate for Time to Emergence of New Metastatic Lesion (TNL) as of 19 October 2015
Description
TNL was defined as time from the randomization date to the first day of radiological progression that included new metastatic lesions. Participants with no new metastatic lesions were censored at the date of the most recent radiological assessment.
Time Frame
up to 36 months
Title
Percentage of Participants With Progressive Disease Due to Any New Metastatic Lesion as of 19 October 2015
Description
Progressive disease was due to either new metastatic lesions only or new metastatic lesions and target tumor growth.
Time Frame
up to 36 months
Title
Participants With Treatment-Emergent Adverse Events as of 23 December 2015
Description
Treatment-emergent adverse events (AEs) were defined as AEs that occurred from the time of first dose through 30 days after the last dose of study medication. The Investigator graded the severity of AEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) criteria: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death A Serious AE (SAE) is defined as any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or constitutes an important medical event.
Time Frame
up to 36 months
Title
Patient-Reported Quality of Life as Measured by the European Quality Of Life - Five Dimensions - Three Levels (EQ-5D-3L) Survey
Description
The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. An overall EQ-5D-3L index was calculated (see EuroQoL website, http://www.euroqol.org/eq-5d-products/eq-5d-3l.html), with an index of 1.0 representing full health and and "0" represents dead, with some health states being worse than dead (<"0"). This study stopped prematurely due to futility and development of this product ceased. The sponsor made a decision at that time to not analyze this outcome. The sponsor no longer has staff or capabilities for further analysis.
Time Frame
Day 1 (pre-treatment), Day 63 (Cycle 3 Day 1), Day 105 (Cycle 5 Day 1) and end of trial
Title
Patient-Reported Symptom Improvement as Measured by the Functional Assessment of Cancer Therapy - Lung (FACT-L) Version 4 Test
Description
The FACT-L contains 4 general subscales and a Lung Cancer Subscale (LCS). General subscales include: Physical Well-Being (PWB), Social/ Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). The LCS assesses symptoms commonly reported by lung cancer patients (e.g., shortness of breath, weight loss, and tightness in the chest). The FACT-L total score ranges from 0 to 136, higher scores represent better QOL. Data were not summarized due to the early termination of the study due to futility.
Time Frame
Day 1 (pre-treatment), Day 63 (Cycle 3 Day 1), Day 105 (Cycle 5 Day 1) and end of trial
Other Pre-specified Outcome Measures:
Title
Exploratory Biomarker Analyses
Description
Exploratory biomarker analyses was to assess correlation between biomarkers and clinical outcome. However, this study stopped prematurely due to futility and development of this product ceased. The sponsor made a decision at that time to not analyze this outcome. The sponsor no longer has staff or capabilities for further analysis.
Time Frame
up to 36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC) Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1 Prior therapy defined as 1 prior systemic therapy for advanced disease Documented disease progression during or following most first line therapy for advanced disease Adequate hematologic, hepatic, renal function Exclusion Criteria: Epidermal growth factor receptor (EGFR) mutations Anaplastic lymphoma kinase (ALK) translocations Predominantly squamous, adenosquamous or unclear histologic type Active or untreated central nervous system (CNS) metastases Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin Serious cardiac illness or medical conditions Pregnant or lactating women Uncontrolled intercurrent illness
Facility Information:
Facility Name
Arizona Oncology Associates PC- NAHOA
City
Flagstaff
State/Province
Arizona
ZIP/Postal Code
86001
Country
United States
Facility Name
Arizona Oncology Associates, PC- NAHOA
City
Prescott Valley
State/Province
Arizona
ZIP/Postal Code
86314
Country
United States
Facility Name
Northern Arizona Hematology & Oncology Associates
City
Sedona
State/Province
Arizona
ZIP/Postal Code
86336
Country
United States
Facility Name
Arizona Clinical Research Center, Inc.
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85715
Country
United States
Facility Name
Pacific Cancer Medical Center, Inc
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Comprehensive Blood & Cancer Center
City
Bakersfield
State/Province
California
ZIP/Postal Code
93309
Country
United States
Facility Name
City of Hope Comprehensive Breast Cancer Center
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Facility Name
UC San Diego Moores Cancer Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
Loma Linda University Cancer Center
City
Loma Linda
State/Province
California
ZIP/Postal Code
92345
Country
United States
Facility Name
VA Greater Los Angeles Healthcare System
City
Los Angeles
State/Province
California
ZIP/Postal Code
90073
Country
United States
Facility Name
Ronald Reagan UCLA Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
St. Joseph Hospital, Center for Cancer Prevention and Treatment
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Cancer Care Associates Medical Group, Inc.
City
Redondo Beach
State/Province
California
ZIP/Postal Code
90277
Country
United States
Facility Name
UC Davis Medical Center - UC Davis Comprehensive Cancer
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Facility Name
Santa Barbara Hematology Oncology Medical Group, Inc.
City
Santa Barbara
State/Province
California
ZIP/Postal Code
93105-4230
Country
United States
Facility Name
City of Hope- South Pasadena
City
South Pasadena
State/Province
California
ZIP/Postal Code
91030
Country
United States
Facility Name
Rocky Mountain Cancer Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Facility Name
Eastern Connecticut Hematology Associates
City
Norwich
State/Province
Connecticut
ZIP/Postal Code
06360
Country
United States
Facility Name
Medical Oncology Hematology Consultants, PA
City
Newark
State/Province
Delaware
ZIP/Postal Code
19713
Country
United States
Facility Name
Lynn Cancer Institute Center for Hematology Oncology
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
Facility Name
Halifax Health - Medical Center
City
Daytona Beach
State/Province
Florida
ZIP/Postal Code
32114
Country
United States
Facility Name
University of Miami Health System Sylvester at Deerfield Beach
City
Deerfield Beach
State/Province
Florida
ZIP/Postal Code
33442-7753
Country
United States
Facility Name
Memorial Regional Hospital
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Facility Name
Baptist Health Medical Group Oncology, LLC
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Facility Name
University of South Florida - H. Lee Moffitt
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
Palm Beach Cancer Institute
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
Facility Name
Emory University - Winship Cancer Institute
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Northwest Georgia Oncology Centers, PC
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
University Of Chicago Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
Cancer Care Specialists of Central Illinois, S.C.
City
Decatur
State/Province
Illinois
ZIP/Postal Code
62526
Country
United States
Facility Name
Saint Anthony Medical Center
City
Rockford
State/Province
Illinois
ZIP/Postal Code
61108
Country
United States
Facility Name
Fort Wayne Medical Oncology and Hematology Inc
City
Fort Wayne
State/Province
Indiana
ZIP/Postal Code
46804
Country
United States
Facility Name
AAMC Oncology and Hematology
City
Annapolis
State/Province
Maryland
ZIP/Postal Code
21401
Country
United States
Facility Name
The Center for Cancer and Blood Disorders (CCBD) - Bethesda
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20817
Country
United States
Facility Name
The John R Marsh Cancer Center
City
Hagerstown
State/Province
Maryland
ZIP/Postal Code
21742
Country
United States
Facility Name
Dana Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Dana Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Henry Ford Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Sparrow Regional Cancer Center
City
Lansing
State/Province
Michigan
ZIP/Postal Code
48909
Country
United States
Facility Name
St. Luke's Hospital Duluth
City
Duluth
State/Province
Minnesota
ZIP/Postal Code
55805
Country
United States
Facility Name
Frauenshuh Cancer Center
City
Saint Louis Park
State/Province
Minnesota
ZIP/Postal Code
55426
Country
United States
Facility Name
St. Louis Cancer Care, LLP - North County
City
Bridgeton
State/Province
Missouri
ZIP/Postal Code
63044
Country
United States
Facility Name
Renown Regional Medical Center
City
Reno
State/Province
Nevada
ZIP/Postal Code
89502
Country
United States
Facility Name
Hackensack University Medical Center - John Theurer Cancer Center
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Facility Name
New Mexico Cancer Center
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87109
Country
United States
Facility Name
North Shore Hematology Oncology Associates
City
East Setauket
State/Province
New York
ZIP/Postal Code
11733
Country
United States
Facility Name
Clinical Research Alliance
City
Lake Success
State/Province
New York
ZIP/Postal Code
11042
Country
United States
Facility Name
University Of North Carolina At Chapel Hill
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Facility Name
Novant Health Presbyterian Medical Center
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Facility Name
New Hanover Regional Medical Center - Zimmer Cancer Center
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Novant Health Oncology Specialists
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
Tulsa Cancer Institute, PLLC
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74146
Country
United States
Facility Name
Kaiser Permanente Northwest
City
Portland
State/Province
Oregon
ZIP/Postal Code
97227
Country
United States
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Facility Name
Guthrie Medical Group, PC
City
Sayre
State/Province
Pennsylvania
ZIP/Postal Code
18840
Country
United States
Facility Name
Rapid City Regional Hospital
City
Rapid City
State/Province
South Dakota
ZIP/Postal Code
57701
Country
United States
Facility Name
Prairie Lakes Healthcare System
City
Watertown
State/Province
South Dakota
ZIP/Postal Code
57201
Country
United States
Facility Name
Erlanger Institute for Clinical Research
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37403
Country
United States
Facility Name
Associates In Oncology and Hematology
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37421
Country
United States
Facility Name
Thompson Cancer Survival Center
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37916
Country
United States
Facility Name
Texas Oncology-Arlington North
City
Arlington
State/Province
Texas
ZIP/Postal Code
76012
Country
United States
Facility Name
Texas Oncology - Arlington South
City
Arlington
State/Province
Texas
ZIP/Postal Code
76014
Country
United States
Facility Name
Texas Oncology, P.A.
City
Beaumont
State/Province
Texas
ZIP/Postal Code
77702
Country
United States
Facility Name
Texas Oncology, PA
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Facility Name
Simmons Comprehensive Cancer Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Facility Name
Houston Methodist Hospital Research Institute
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Millennium Oncology
City
Houston
State/Province
Texas
ZIP/Postal Code
77090
Country
United States
Facility Name
Joe Arrington Cancer Research and Treatment Center
City
Lubbock
State/Province
Texas
ZIP/Postal Code
79410
Country
United States
Facility Name
Cancer Care Centers Of South Texas
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78212
Country
United States
Facility Name
Cancer Care Centers Of South Texas
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78217
Country
United States
Facility Name
Cancer Care Centers of South Texas
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78258
Country
United States
Facility Name
Texas Oncology - Sherman
City
Sherman
State/Province
Texas
ZIP/Postal Code
75090
Country
United States
Facility Name
Providence Regional Medical Center Everett
City
Everett
State/Province
Washington
ZIP/Postal Code
98201
Country
United States
Facility Name
Cancer Care Northwest
City
Spokane Valley
State/Province
Washington
ZIP/Postal Code
99216
Country
United States
Facility Name
Northwest Medical Specialties, PLLC
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Facility Name
Mary Babb Cancer Center
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26506
Country
United States
Facility Name
Green Bay Oncology, Ltd. - St. Mary's Site
City
Green Bay
State/Province
Wisconsin
ZIP/Postal Code
54303-3216
Country
United States
Facility Name
Green Bay Oncology
City
Green Bay
State/Province
Wisconsin
ZIP/Postal Code
54307
Country
United States
Facility Name
Landesklinikum Krems
City
Krems
State/Province
Niederösterreich
ZIP/Postal Code
3500
Country
Austria
Facility Name
Krankenhaus Der Barmherzigen Schwestern
City
Linz
State/Province
Oberösterreich
ZIP/Postal Code
4010
Country
Austria
Facility Name
Klinikum Wels-Grieskirchen
City
Wels
State/Province
Oberösterreich
ZIP/Postal Code
A-4600
Country
Austria
Facility Name
Bezirkskrankenhaus Kufstein [Onkologie]
City
Kufstein
State/Province
Tirol
ZIP/Postal Code
A-6330
Country
Austria
Facility Name
Allgemeines Krankenhaus Linz
City
Linz
ZIP/Postal Code
4021
Country
Austria
Facility Name
Elisabeth Linz Hospital
City
Linz
ZIP/Postal Code
4021
Country
Austria
Facility Name
Otto Wagner Spital
City
Wien
ZIP/Postal Code
1140
Country
Austria
Facility Name
Sozialmedizinisches Zentrum Baumgartner Höhe
City
Wien
ZIP/Postal Code
1145
Country
Austria
Facility Name
AZ Sint-Maarten - Campus Leopoldstraat
City
Mechelen
State/Province
Antwerpen
ZIP/Postal Code
2800
Country
Belgium
Facility Name
Clinique Saint-Pierre Ottignies
City
Ottignies
State/Province
Brabant Wallon
ZIP/Postal Code
1340
Country
Belgium
Facility Name
Grand Hôpital de Charleroi - Site Notre-Dame
City
Charleroi
State/Province
Hainaut
ZIP/Postal Code
6000
Country
Belgium
Facility Name
INDC Entité Jolimontoise - Polyclinique de Jolimont
City
Haine St. Paul
State/Province
Hainaut
ZIP/Postal Code
1700
Country
Belgium
Facility Name
CHU Dinant Godinne UCL Namur
City
Yvoir
State/Province
Namur
ZIP/Postal Code
5533
Country
Belgium
Facility Name
Algemeen Stedelijk Ziekenhuis - Campus Aalst
City
Roeselaere
State/Province
West-Vlaanderen
ZIP/Postal Code
8800
Country
Belgium
Facility Name
Cliniques Universitaire Saint-Luc
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Facility Name
CHR de la Citadelle - Site Citadelle
City
Liège
ZIP/Postal Code
4000
Country
Belgium
Facility Name
Clinical Centre Banja Luka
City
Banja Luka
State/Province
Republika Srpska
ZIP/Postal Code
78000
Country
Bosnia and Herzegovina
Facility Name
University Clinical Center Tuzla
City
Tuzla
State/Province
Tuzlanski kanton
ZIP/Postal Code
75000
Country
Bosnia and Herzegovina
Facility Name
Clinical Hospital Mostar
City
Mostar
ZIP/Postal Code
88108
Country
Bosnia and Herzegovina
Facility Name
Clinical Center University of Sarajevo, Clinic of Oncology
City
Sarajevo
ZIP/Postal Code
71000
Country
Bosnia and Herzegovina
Facility Name
University Clinical Centre Sarajevo
City
Sarajevo
ZIP/Postal Code
71000
Country
Bosnia and Herzegovina
Facility Name
University Clinical Center Tuzla
City
Tuzla
ZIP/Postal Code
75000
Country
Bosnia and Herzegovina
Facility Name
Kantonalna bolnica Zenica
City
Zenica
ZIP/Postal Code
72000
Country
Bosnia and Herzegovina
Facility Name
Princess Margaret Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
MG5 2M9
Country
Canada
Facility Name
Mc Gill University-MUHC
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2W 1S6
Country
Canada
Facility Name
University Hospital Center Zagreb
City
Zagreb
State/Province
Grad Zagreb
ZIP/Postal Code
10 000
Country
Croatia
Facility Name
Opca bolnica Pula
City
Pula
State/Province
Istarska županija
ZIP/Postal Code
52000
Country
Croatia
Facility Name
Fakultni nemocnice Olomouc
City
Olomouc
ZIP/Postal Code
775 20
Country
Czech Republic
Facility Name
Fakultni nemocnice Ostrava
City
Ostrava - Poruba
ZIP/Postal Code
708 52
Country
Czech Republic
Facility Name
Vseobecna fakultni nemocnice v Praze
City
Prague
ZIP/Postal Code
128 08
Country
Czech Republic
Facility Name
Nemocnice Na Bulovce
City
Prague
ZIP/Postal Code
180 81
Country
Czech Republic
Facility Name
CHI des Alpes du Sud
City
Gap
State/Province
Hautes-Alpes
ZIP/Postal Code
5000
Country
France
Facility Name
Centre D'Oncologie Du Pays Basque
City
Bayonne
State/Province
Pyrénées-Atlantiques
ZIP/Postal Code
64100
Country
France
Facility Name
Centre Hosptalier De Villefranche-Sur-Saone
City
Villefranche Sur Saone
State/Province
Rhône
ZIP/Postal Code
69655
Country
France
Facility Name
Chi creteil
City
Creteil
State/Province
Val-de-Marne
ZIP/Postal Code
94010
Country
France
Facility Name
Chu De Grenoble - Hopital Michallon
City
Grenoble
ZIP/Postal Code
38700
Country
France
Facility Name
Centre Léon Bérard
City
Lyon
ZIP/Postal Code
69373
Country
France
Facility Name
Groupe Hospitalier Cochin
City
Paris
ZIP/Postal Code
75679
Country
France
Facility Name
Centre Hospitalier Universitaire de Rennes - Hopital d
City
Rennes
ZIP/Postal Code
35033
Country
France
Facility Name
Hôpital Charles Nicolle
City
Rouen
ZIP/Postal Code
76000
Country
France
Facility Name
CHRU de Strasbourg
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Facility Name
Universitätsklinikum Freiburg
City
Freiburg
State/Province
Baden-Württemberg
ZIP/Postal Code
79106
Country
Germany
Facility Name
Universiaetsklinikum Ulm
City
Ulm
State/Province
Baden-Württemberg
ZIP/Postal Code
89081
Country
Germany
Facility Name
Schwarzwald-Baar-Klinikum
City
Villingen-Schwenningen
State/Province
Baden-Württemberg
ZIP/Postal Code
78052
Country
Germany
Facility Name
Asklepios Fachklinik München-Gauting
City
Gauting
State/Province
Bayern
ZIP/Postal Code
82131
Country
Germany
Facility Name
Klinikum Bogenhausen
City
Muenchen
State/Province
Bayern
ZIP/Postal Code
81925
Country
Germany
Facility Name
Gesundheitszentrum Wetterau
City
Bad Nauheim
State/Province
Hessen
ZIP/Postal Code
61231
Country
Germany
Facility Name
Johann Wolfgang Goethe University Clinic Frankfurt
City
Frankfurt
State/Province
Hessen
ZIP/Postal Code
60590
Country
Germany
Facility Name
Johann Wolfgang Goethe University Clinic Frankfurt
City
Frankfurt
State/Province
Hessen
ZIP/Postal Code
D-60590
Country
Germany
Facility Name
Klinikum Kassel
City
Kassel
State/Province
Hessen
ZIP/Postal Code
34125
Country
Germany
Facility Name
Kliniken der Stadt Köln gGmbH
City
Köln
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
51109
Country
Germany
Facility Name
Universitaetsklinikum des Saarlandes
City
Homburg
State/Province
Saarland
ZIP/Postal Code
66421
Country
Germany
Facility Name
Universitätsklinikum Leipzig [Pneumologie]
City
Leipzig
State/Province
Sachsen
ZIP/Postal Code
04103
Country
Germany
Facility Name
Pneumologisches Forschungsinstitut an der Lungenclinic Gross
City
Großhansdorf
State/Province
Schleswig-Holstein
ZIP/Postal Code
22927
Country
Germany
Facility Name
MVZ Äerzteforum Seestraße
City
Berlin
ZIP/Postal Code
13347
Country
Germany
Facility Name
Ev. Krankenhaus Bielefeld
City
Bielefeld
ZIP/Postal Code
33611
Country
Germany
Facility Name
Klinikum Frankfurt An Der Oder
City
Frankfurt/Oder
ZIP/Postal Code
15236
Country
Germany
Facility Name
Practice Laack
City
Hamburg
ZIP/Postal Code
20251
Country
Germany
Facility Name
Unikl. Schleswig-Holstein - Lübeck
City
Lübeck
ZIP/Postal Code
23538
Country
Germany
Facility Name
J. Gutenberg Uni.Mainz
City
Mainz
ZIP/Postal Code
55101
Country
Germany
Facility Name
Medizinische Fakultät Mannheim Uni Heidelberg
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Facility Name
Gemeinschaftspraxis fuer Haematologie und Onkologie
City
Muenster
ZIP/Postal Code
48149
Country
Germany
Facility Name
Klinikum Offenbach GmbH
City
Offenbach
ZIP/Postal Code
63069
Country
Germany
Facility Name
Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkó
City
Deszk
State/Province
Csongrád
ZIP/Postal Code
6772
Country
Hungary
Facility Name
Fejér Megyei Szent György Egyetemi Oktató Kórház
City
Székesfehérvár
State/Province
Fejér
ZIP/Postal Code
8000
Country
Hungary
Facility Name
Országos Korányi TBC és Pulmonológiai Intézet
City
Budapest
State/Province
Pest
ZIP/Postal Code
1145
Country
Hungary
Facility Name
Semmelweis Egyetem
City
Budapest
ZIP/Postal Code
1125
Country
Hungary
Facility Name
Országos Korányi TBC és Pulmonológiai Intézet
City
Budapest
ZIP/Postal Code
1529
Country
Hungary
Facility Name
Békés Megyei Pándy Kálmán Kórház
City
Gyula
ZIP/Postal Code
5703
Country
Hungary
Facility Name
CRU Hungary Kft.
City
Miskolc
ZIP/Postal Code
3529
Country
Hungary
Facility Name
Irccs Irst
City
Meldola
State/Province
Forli
ZIP/Postal Code
47014
Country
Italy
Facility Name
Presidio Ospedaliero Centrale Belcolle, AUSL Viterbo
City
Viterbo
State/Province
Lazio
ZIP/Postal Code
01100
Country
Italy
Facility Name
Azienda Ospedaliera San Gerardo
City
Monza
State/Province
Lombardia
ZIP/Postal Code
20900
Country
Italy
Facility Name
CRO, IRCCS, Istituto Nazionale Tumori
City
Aviano
State/Province
Pordenone
ZIP/Postal Code
33081
Country
Italy
Facility Name
Azienda Policlinico Umberto I
City
Rome
State/Province
Roma
ZIP/Postal Code
00161
Country
Italy
Facility Name
Policlinico S.Orsola Malpighi, AOU di Bologna
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Facility Name
AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can
City
Genova
ZIP/Postal Code
16132
Country
Italy
Facility Name
Istituto Europeo di Oncologia, Istituto di Ricovero e Cura a
City
Milano
ZIP/Postal Code
20141
Country
Italy
Facility Name
Iov-Irccs
City
Padova
ZIP/Postal Code
35128
Country
Italy
Facility Name
Ospedale S.Maria della Misericordia, AO di Perugia, Universi
City
Perugia
ZIP/Postal Code
06156
Country
Italy
Facility Name
Ospedale Guglielmo da Saliceto, AUSL Piacenza
City
Piacenza
ZIP/Postal Code
29100
Country
Italy
Facility Name
Istituti Fisioterapici Ospitalieri Regina Elena
City
Roma
ZIP/Postal Code
00144
Country
Italy
Facility Name
Borgo Roma, Policlinico G.Rossi, AOU Integrata Verona
City
Verona
ZIP/Postal Code
37134
Country
Italy
Facility Name
Ziekenhuis Assen
City
Assen
State/Province
Drenthe
ZIP/Postal Code
9401 RK
Country
Netherlands
Facility Name
Ziekenhuis St Jansdal
City
Harderwijk
State/Province
Gelderland
ZIP/Postal Code
3844 DG
Country
Netherlands
Facility Name
Gelre Ziekenhuis Zutphen
City
Zutphen
State/Province
Gelderland
ZIP/Postal Code
7207 AE
Country
Netherlands
Facility Name
academisch ziekenhuis Maastricht
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6229 HX
Country
Netherlands
Facility Name
Isala Klinieken Zwolle
City
Zwolle
State/Province
Overijssel
ZIP/Postal Code
8025 AB
Country
Netherlands
Facility Name
Sint Antoniusziekenhuis, location Utrecht
City
Utrecht
ZIP/Postal Code
3543 AZ
Country
Netherlands
Facility Name
Wojewodzki Szpital Specjalistyczny im. M.Kopernika
City
Lodz
State/Province
Lodzkie
ZIP/Postal Code
93-513
Country
Poland
Facility Name
Medica Pro Familia Sp. z o.o. S.K.A.
City
Krakow
State/Province
Malopolskie
ZIP/Postal Code
31-002
Country
Poland
Facility Name
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy
City
Otwock
State/Province
Mazowieckie
ZIP/Postal Code
05-400
Country
Poland
Facility Name
Centrum Onkologii - Instytut im. Marii Sklodowskiej - Curie
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-781
Country
Poland
Facility Name
Uniwersytecki Szpital Kliniczny w Bialymstoku
City
Bialystok
State/Province
Podlaskie
ZIP/Postal Code
15-540
Country
Poland
Facility Name
Szpital Wojewodzki w Lomzy im. Kardynala S. Wyszynskiego
City
Lomza
State/Province
Podlaskie
ZIP/Postal Code
18-400
Country
Poland
Facility Name
Szpital Wojewodzki Zespolony
City
Elblag
State/Province
Warminsko-mazurskie
ZIP/Postal Code
82-300
Country
Poland
Facility Name
NZOZ Med Polonia
City
Poznan
State/Province
Wielkopolskie
ZIP/Postal Code
60-693
Country
Poland
Facility Name
Wielkopolskie Centrum Pulmonologii i Torakochirurgii
City
Poznan
State/Province
Wielkopolskie
ZIP/Postal Code
60569
Country
Poland
Facility Name
Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc
City
Olsztyn
ZIP/Postal Code
10-357
Country
Poland
Facility Name
Szpital Chorob Pluc im. Sw. Jozefa w Pilchowicach
City
Pilchowice
ZIP/Postal Code
44145
Country
Poland
Facility Name
Szpital Specjalistyczny
City
Prabuty
ZIP/Postal Code
82-550
Country
Poland
Facility Name
Institutul Oncologic "Prof. Dr. Alex. Trestioreanu"
City
Bucharest
ZIP/Postal Code
022328
Country
Romania
Facility Name
Spitalul Universitar de Urgenta Bucuresti
City
Bucharest
ZIP/Postal Code
050098
Country
Romania
Facility Name
Spitalul Clinic Coltea
City
Bucuresti
ZIP/Postal Code
030171
Country
Romania
Facility Name
Institutul Oncologic "Prof.Dr.I.Chiricuta" Cluj Napoca
City
Cluj Napoca
ZIP/Postal Code
400015
Country
Romania
Facility Name
Medisprof
City
Cluj Napoca
ZIP/Postal Code
400058
Country
Romania
Facility Name
Institutul Oncologic "Prof.Dr.I.Chiricuta" Cluj Napoca
City
Cluj-Napoca
ZIP/Postal Code
400015
Country
Romania
Facility Name
Centrul de Oncologie Sf. Nectarie
City
Craiova
ZIP/Postal Code
200385
Country
Romania
Facility Name
Institutul Regional de Oncologie Iasi
City
Iasi
ZIP/Postal Code
700483
Country
Romania
Facility Name
Oncomed
City
Timisoara
ZIP/Postal Code
300239
Country
Romania
Facility Name
Synta Pharmaceuticals Investigational Site
City
Chelyabinsk
ZIP/Postal Code
454087
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Ekaterinburg
ZIP/Postal Code
620036
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Ivanovo
ZIP/Postal Code
153040
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Izhevsk
ZIP/Postal Code
426067
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Kemerovo
ZIP/Postal Code
650036
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Krasnoyarsk
ZIP/Postal Code
660133
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Kursk
ZIP/Postal Code
305035
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Lipetsk
ZIP/Postal Code
398005
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Moscow
ZIP/Postal Code
115478
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Nizhny Novgorod
ZIP/Postal Code
603081
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Novosibirsk
ZIP/Postal Code
630047
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Omsk
ZIP/Postal Code
644013
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Orel
ZIP/Postal Code
302020
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Rostov-on-Don
ZIP/Postal Code
344037
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Samara
ZIP/Postal Code
443031
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Saransk
ZIP/Postal Code
430032
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Sochi
ZIP/Postal Code
354057
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
St. Petersburg
ZIP/Postal Code
194017
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
St. Petersburg
ZIP/Postal Code
197758
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
St. Petersburg
ZIP/Postal Code
198255
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Stavropol
ZIP/Postal Code
355047
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Ufa
ZIP/Postal Code
450000
Country
Russian Federation
Facility Name
Synta Pharmaceuticals Investigational Site
City
Ufa
ZIP/Postal Code
450054
Country
Russian Federation
Facility Name
Clinical Centre of Serbia
City
Beograd
State/Province
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Clinical Centre Nis
City
Nis
State/Province
Nišavski okrug
ZIP/Postal Code
18000
Country
Serbia
Facility Name
Institute for Oncology and Radiology of Serbia
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Institute for pulmonary diseases of Vojvodine
City
Sremska Kamenica
ZIP/Postal Code
21204
Country
Serbia
Facility Name
Clinical Center Kragujevac
City
Kragujevac
State/Province
Šumadijski okrug
ZIP/Postal Code
34 000
Country
Serbia
Facility Name
Univerzitetna klinika za pljucne bolesti in alergijo Golnik
City
Golnik
ZIP/Postal Code
4204
Country
Slovenia
Facility Name
Onkoloski institut Ljubljana
City
Ljubljana
ZIP/Postal Code
1000
Country
Slovenia
Facility Name
Xerencia de Xestión Integrada A Coruña Hospital Teresa Herrera
City
La Coruña
State/Province
A Coruña
ZIP/Postal Code
15006
Country
Spain
Facility Name
Synta Pharmaceuticals Investigational Site
City
Málaga
State/Province
Andalucía
ZIP/Postal Code
29010
Country
Spain
Facility Name
Synta Pharmaceuticals Investigational Site
City
Oviedo
State/Province
Asturias
ZIP/Postal Code
33006
Country
Spain
Facility Name
H. Son Llàtzer
City
Palma de Mallorca
State/Province
Baleares
ZIP/Postal Code
07198
Country
Spain
Facility Name
Hospital de Mataró, Consorci Sanitari del Maresme
City
Mataró
State/Province
Barcelona
ZIP/Postal Code
08304
Country
Spain
Facility Name
Synta Pharmaceuticals Investigational Site
City
Santander
State/Province
Cantabria
ZIP/Postal Code
39008
Country
Spain
Facility Name
Onkologikoa
City
San Sebastian
State/Province
Guipuzcoa
ZIP/Postal Code
20014
Country
Spain
Facility Name
Hospital Universitari Germans Trias i Pujol
City
Badalona
ZIP/Postal Code
08916
Country
Spain
Facility Name
H.U. Vall d'Hebrón
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Synta Pharmaceuticals Investigational Site
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
H.U. Reina Sofía
City
Córdoba
ZIP/Postal Code
14004
Country
Spain
Facility Name
Synta Pharmaceuticals Investigational Site
City
Girona
ZIP/Postal Code
17007
Country
Spain
Facility Name
Synta Pharmaceuticals Investigational Site
City
Madrid
ZIP/Postal Code
28033
Country
Spain
Facility Name
Hospital Universitario Ramón y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
Synta Pharmaceuticals Investigational Site
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
F. Jiménez Diaz
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Synta Pharmaceuticals Investigational Site
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Hospital Madrid Norte Sanchinarro
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Facility Name
Synta Pharmaceuticals Investigational Site
City
Madrid
ZIP/Postal Code
28223
Country
Spain
Facility Name
Hospital Universitario Virgen del Rocío
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Facility Name
Hospital Universitari i Politecnic La Fe
City
Valencia
ZIP/Postal Code
460026
Country
Spain
Facility Name
Synta Pharmaceuticals Investigational Site
City
Cherkasy
ZIP/Postal Code
18009
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Chernivtsi
ZIP/Postal Code
58013
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Dnepropetrovsk
ZIP/Postal Code
49102
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Donetsk
ZIP/Postal Code
83087
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Donetsk
ZIP/Postal Code
83092
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Ivano-Frankivsk
ZIP/Postal Code
76000
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigative Site
City
Kharkiv
ZIP/Postal Code
61070
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Khmelnytskyi
ZIP/Postal Code
29009
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Kirovohrad
ZIP/Postal Code
25011
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Kryvyi Rih
ZIP/Postal Code
50048
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Kyiv
ZIP/Postal Code
03115
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Makiivka
ZIP/Postal Code
86120
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Poltava
ZIP/Postal Code
36011
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Simferopol
ZIP/Postal Code
95023
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Sumy
ZIP/Postal Code
40022
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Uzhhorod
ZIP/Postal Code
88014
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Vinnytsia
ZIP/Postal Code
21021
Country
Ukraine
Facility Name
Synta Pharmaceuticals Investigational Site
City
Truro
State/Province
Cornwall
ZIP/Postal Code
TR1 3LJ
Country
United Kingdom
Facility Name
Synta Pharmaceuticals Investigational Site
City
Shrewsbury
State/Province
Shropshire
ZIP/Postal Code
SY3 8XQ
Country
United Kingdom
Facility Name
Synta Pharmaceuticals Investigational Site
City
Sutton
State/Province
Surrey
ZIP/Postal Code
SM2 5PT
Country
United Kingdom
Facility Name
Synta Pharmaceuticals Investigational Site
City
Swindon
State/Province
Wiltshire
ZIP/Postal Code
SN3 6BB
Country
United Kingdom
Facility Name
Synta Pharmaceuticals Investigational Site
City
Cardiff
ZIP/Postal Code
CF14 2TL
Country
United Kingdom
Facility Name
Synta Pharmaceuticals Investigational Site
City
Edinburgh
ZIP/Postal Code
EH4 2XU
Country
United Kingdom
Facility Name
Synta Pharmaceuticals Investigational Site
City
Leicester
ZIP/Postal Code
LEI 5WW
Country
United Kingdom
Facility Name
Synta Pharmaceuticals Investigational Site
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Facility Name
Synta Pharmaceuticals Investigational Site
City
London
ZIP/Postal Code
SW3 6JJ
Country
United Kingdom
Facility Name
Synta Pharmaceuticals Investigational Site
City
London
ZIP/Postal Code
W6 8RF
Country
United Kingdom
Facility Name
Synta Pharmaceuticals Investigational Site
City
Nottingham
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Facility Name
Synta Pharmaceuticals Investigational Site
City
Southampton
ZIP/Postal Code
SO16 6YD
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

We'll reach out to this number within 24 hrs